Ratings by JPMorgan (Brian Cheng)
| Date | Company | Symbol | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 4/2/2024 | Roivant Sciences | ROIV | Maintain | Overweight (N/A) |
|
Details | ||
| 3/22/2024 | Precigen Inc. | PGEN | Downgrade | Underweight (Neutral) |
1.44 (1.32) |
-8.33% | Details | |
| 3/19/2024 | Mersana | MRSN | Upgrade | Neutral (Underweight) |
5.04 (3.34) |
-33.73% | Details | |
| 3/12/2024 | Zymeworks | ZYME | Maintain | Neutral (N/A) |
|
Details | ||
| 3/5/2024 | Metagenomi Inc | MGX | New Coverage | Overweight (N/A) |
12.00 (7.75) |
-35.42% | Details | |
| 3/4/2024 | Kyverna Therapeutics Inc | KYTX | New Coverage | Overweight (N/A) |
27.17 (19.01) |
-30.03% | Details | |
| 2/28/2024 | Protagonist Therapeutics | PTGX | Maintain | Overweight (N/A) |
|
Details | ||
| 2/27/2024 | Allogene | ALLO | Maintain | Overweight (N/A) |
|
Details | ||
| 2/27/2024 | Editas Medicine | EDIT | Maintain | Neutral (N/A) |
|
Details | ||
| 2/20/2024 | Immunovant | IMVT | New Coverage | Overweight (N/A) |
37.80 (28.32) |
-25.08% | Details | |
| 1/30/2024 | Cargo Therapeutics | CRGX | Maintain | Overweight (N/A) |
|
Details | ||
| 12/5/2023 | Cargo Therapeutics | CRGX | New Coverage | Overweight (N/A) |
16.29 (19.10) |
17.25% | Details | |
| 11/10/2023 | Xencor, Inc. | XNCR | Maintain | Overweight (N/A) |
|
Details | ||
| 11/10/2023 | Zymeworks | ZYME | Maintain | Neutral (N/A) |
|
Details | ||
| 10/18/2023 | Editas Medicine | EDIT | Upgrade | Neutral (Underweight) |
6.81 (5.55) |
-18.5% | Details | |
| 10/2/2023 | Xencor, Inc. | XNCR | Maintain | Overweight (N/A) |
|
Details | ||
| 10/2/2023 | Intellia Therapeutics | NTLA | Maintain | Overweight (N/A) |
|
Details | ||
| 9/25/2023 | Protagonist Therapeutics | PTGX | Maintain | Overweight (N/A) |
|
Details | ||
| 9/25/2023 | BioAtla Inc. | BCAB | Maintain | Overweight (N/A) |
|
Details | ||
| 9/25/2023 | Allogene | ALLO | Maintain | Overweight (N/A) |
|
Details | ||
| 8/10/2023 | ADC Therapeutics | ADCT | Upgrade | Neutral (Underweight) |
1.50 (4.76) |
217.33% | Details | |
| 8/2/2023 | BioAtla Inc. | BCAB | Maintain | Overweight (N/A) |
|
Details | ||
| 7/27/2023 | Mersana | MRSN | Downgrade | Underweight (Neutral) |
3.91 (3.34) |
-14.58% | Details | |
| 6/16/2023 | Mersana | MRSN | Downgrade | Neutral (Overweight) |
9.55 (3.34) |
-65.03% | Details | |
| 6/1/2023 | Adicet Bio Inc. | ACET | Downgrade | Neutral (Overweight) |
5.48 (2.03) |
-62.96% | Details | |
| 5/23/2023 | Precigen Inc. | PGEN | New Coverage | Neutral (N/A) |
1.29 (1.32) |
2.33% | Details | |
| 5/9/2023 | Xencor, Inc. | XNCR | Maintain | Overweight (N/A) |
|
Details | ||
| 4/3/2023 | BioAtla Inc. | BCAB | Maintain | Overweight (N/A) |
|
Details | ||
| 3/31/2023 | Intellia Therapeutics | NTLA | Maintain | Overweight (N/A) |
|
Details | ||
| 3/31/2023 | Zymeworks | ZYME | Maintain | Neutral (N/A) |
|
Details | ||
| 3/17/2023 | Adicet Bio Inc. | ACET | Maintain | (Overweight) |
|
Details | ||
| 3/16/2023 | Mersana | MRSN | Upgrade | Overweight (Neutral) |
4.55 (9.55) |
109.89% | Details | |
| 3/7/2023 | Protagonist Therapeutics | PTGX | Maintain | Overweight (N/A) |
|
Details | ||
| 2/24/2023 | Xencor, Inc. | XNCR | Maintain | Overweight (N/A) |
|
Details | ||
| 2/13/2023 | Xencor, Inc. | XNCR | Maintain | Overweight (N/A) |
|
Details | ||
| 1/24/2023 | Allogene | ALLO | Upgrade | Overweight (Neutral) |
6.55 (3.46) |
-47.18% | Details | |
| 12/16/2022 | Senti Biosciences, Inc. | SNTI | New Coverage | Neutral (N/A) |
1.52 (0.29) |
-80.92% | Details | |
| 12/7/2022 | Gossamer Bio Inc. | GOSS | Downgrade | Underweight (Neutral) |
9.29 (0.81) |
-91.28% | Details | |
| 11/10/2022 | Clovis Oncology | CLVS | Downgrade | Underweight (Neutral) |
0.98 (0.08) |
-91.84% | Details | |
| 10/28/2022 | Zymeworks | ZYME | Maintain | Neutral (N/A) |
|
Details | ||
| 9/21/2022 | Gossamer Bio Inc. | GOSS | New Coverage | Neutral (N/A) |
13.60 (0.81) |
-94.04% | Details | |
| 9/21/2022 | Xencor, Inc. | XNCR | New Coverage | Overweight (N/A) |
27.61 (18.95) |
-31.37% | Details | |
| 9/21/2022 | Intellia Therapeutics | NTLA | New Coverage | Overweight (N/A) |
62.53 (21.32) |
-65.9% | Details | |
| 9/21/2022 | ADC Therapeutics | ADCT | New Coverage | Overweight (N/A) |
5.29 (4.76) |
-10.02% | Details | |
| 9/21/2022 | Adicet Bio Inc. | ACET | New Coverage | Overweight (N/A) |
14.81 (2.03) |
-86.29% | Details | |
| 8/2/2022 | Zymeworks | ZYME | New Coverage | Neutral (N/A) |
5.84 (8.67) |
48.46% | Details | |
| 8/2/2022 | Mersana | MRSN | New Coverage | Neutral (N/A) |
5.07 (3.34) |
-34.12% | Details | |
| 8/2/2022 | Protagonist Therapeutics | PTGX | New Coverage | Overweight (N/A) |
9.95 (25.22) |
153.47% | Details | |
| 8/2/2022 | Editas Medicine | EDIT | New Coverage | Underweight (N/A) |
15.91 (6.81) |
-57.2% | Details | |
| 8/2/2022 | Clovis Oncology | CLVS | New Coverage | Neutral (N/A) |
1.67 (0.08) |
-95.21% | Details | |
| 8/2/2022 | BioAtla Inc. | BCAB | New Coverage | Overweight (N/A) |
3.40 (2.43) |
-28.53% | Details | |
| 8/2/2022 | Allogene | ALLO | New Coverage | Neutral (N/A) |
12.98 (3.46) |
-73.34% | Details |
